Vytorin Sales Data

Rank 89 Current sales rank, all
U.S. Pharmaceuticals.

Last updated: February 2014 (updated quarterly).
The following data shows Vytorin U.S. retail sales in Q4 2013 compared to previous quarters.

Date Range Sales Rank Sales ($000) Units (000)
Q4 2013 89 (9) -3.02% -7.40%
Q3 2013 80 (8) -3.87% -3.91%
Q2 2013 72 (1) -2.71% -6.64%
Q1 2013 71 -0.81% -4.30%
Q4 2012 71 (6) -3.06% -5.02%
Q3 2012 65 (6) 6.33% -2.41%
Q2 2012 71 (4) -1.35% -8.16%
Q1 2012 75 (4) -7.25% -7.28%
Q4 2011 71 (10) -3.61% -6.66%
Q3 2011 61 (7) -8.10% -10.72%
Q2 2011 54 -4.04% -7.52%
Q1 2011 54

* Units refer to the number of packages sold.

Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.

Related News

DateArticle
November 3, 2011FDA Panel Backs Expanded use of Merck's Vytorin
June 9, 2011Vytorin Lowers Heart Disease Risk in Large Study of Kidney Patients
November 22, 2010Merck Gets Good News From Vytorin Study
January 9, 2009Update of Safety Review Follow-up to the January 25, 2008 Early Communication about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor)
January 8, 2009FDA Backs Cholesterol Drug Vytorin
September 2, 2008No Definitive Link Seen Between Vytorin and Cancer
August 22, 2008FDA Issues Early Communication About Ongoing Safety Review of Vytorin,  Zocor and Zetia
April 21, 2008Vytorin Coverage with Leading Health Plans Revisited - See Uptake of Generic Simvastatin and Crestor Without Need for Widespread Formulary Changes

Learn about treatments for high cholesterol? Watch video.

Close
Hide
(web3)